Market Cap 23.45B
Revenue (ttm) 3.25B
Net Income (ttm) -1.29B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39.59%
Debt to Equity Ratio 0.02
Volume 2,743,930
Avg Vol 1,094,116
Day's Range N/A - N/A
Shares Out 252.88M
Stochastic %K 89%
Beta 1.27
Analysts Strong Sell
Price Target $123.94

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin a...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 6131 9084
Fax: 49 6131 9084
Address:
An der Goldgrube 12, Mainz, Germany
taxplanr
taxplanr Aug. 20 at 6:46 PM
$BNTX doesn't their ceo like to talk about unpublished results like $MRNA
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 20 at 6:16 PM
ARCT Defies mRNA Selloff And Extends Rally As Moderna, BioNTech Shares Pull Back $ARCT $MRNA $BNTX https://stocktwits.com/news/equity/markets/arct-defies-m-rna-selloff-and-extends-rally-as-moderna-bio-n-tech-shares-pull-back/cZYIDxYRJZZ
0 · Reply
cubie
cubie Aug. 20 at 5:05 PM
$MRNA peas in a pod $BNTX barely down there and $TEM been nice.green all day
0 · Reply
eightytwentie
eightytwentie Aug. 20 at 3:46 PM
$BNTX man just a bunch of bots pumping and peddling other shyt stocks lately on this board
0 · Reply
NodeInvestmentGroup
NodeInvestmentGroup Aug. 20 at 2:52 PM
$BNTX remains a major biotechnology company focused on innovative medicines and next-generation healthcare technologies. AERT’s operating income jumped 310% year over year to $3.4 million, highlighting substantial improvement in core profitability.
0 · Reply
WavefrontSecurities
WavefrontSecurities Aug. 20 at 2:51 PM
$BNTX remains a major biotechnology company focused on innovative medicines and next-generation healthcare technologies. AERT’s operating income jumped 310% year over year to $3.4 million, highlighting substantial improvement in core profitability.
0 · Reply
SmartSigma
SmartSigma Aug. 20 at 2:28 PM
$BNTX I think the most impressive part of the Q2 release is that they did this without massive dilution they are growing organically from sales not from issuing shares that kind of clean growth is very rare and it makes the valuation look even more absurd
0 · Reply
clubb
clubb Aug. 20 at 2:19 PM
$BNTX bullish but still to early to buy
0 · Reply
tkstockpicker
tkstockpicker Aug. 20 at 1:49 PM
$BNTX added
0 · Reply
DonCorleone77
DonCorleone77 Aug. 20 at 11:54 AM
$MRNA $MRK $BNTX Leerink says cancer vaccine win should sustain Merck momentum into fall Leerink notes Merck (MRK) and Moderna (MRNA) announced the top-line recurrence-free survival and distant metastasis-free survival success of the Phase 3 INTerpath-001 study of INT plus pembrolizumab in completed resected Stage IIB to IV melanoma. With this "unexpected Phase 3 success" of intismeran autogene combined with pembrolizumab in adjuvant melanoma, the firm expects positive investor reaction that will sustain momentum for Merck into the fall. The result is also positive, in Leerink's view, for cancer vaccine-levered stocks, but this no longer BioNTech (BNTX) and the firm expects any BioNTech gains today to fade as investors absorb the poor read-through. The firm has an Outperform rating on Merck.
0 · Reply
Latest News on BNTX
BioNTech rises 20.3%

2026-08-19T16:05:37.000Z - 1 day ago

BioNTech rises 20.3%


BioNTech rises 21.6%

2026-08-19T14:00:12.000Z - 1 day ago

BioNTech rises 21.6%


BioNTech price target raised to $142 from $138 at Canaccord

2026-08-05T11:05:37.000Z - 15 days ago

BioNTech price target raised to $142 from $138 at Canaccord


BioNTech price target lowered to $125 from $130 at Citi

2026-08-05T10:35:32.000Z - 15 days ago

BioNTech price target lowered to $125 from $130 at Citi


BioNTech SE Earnings Call Transcript: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 16 days ago

BioNTech SE Earnings Call Transcript: Q2 2026


BioNTech SE Earnings release: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 16 days ago

BioNTech SE Earnings release: Q2 2026


BioNTech SE Slides: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 16 days ago

BioNTech SE Slides: Q2 2026


BioNTech says Sobi's Oelkers will replace Sahin as CEO

Aug 3, 2026, 5:29 AM EDT - 17 days ago

BioNTech says Sobi's Oelkers will replace Sahin as CEO


BioNTech CEO Ugur Sahin to depart, Guido Oelkers to succeed

2026-08-03T09:05:08.000Z - 17 days ago

BioNTech CEO Ugur Sahin to depart, Guido Oelkers to succeed


This Biotech's Cancer Portfolio Could End Its Rough Patch

May 27, 2026, 11:07 AM EDT - 3 months ago

This Biotech's Cancer Portfolio Could End Its Rough Patch


BioNTech SE Transcript: AGM 2026

May 15, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Transcript: AGM 2026


BioNTech Announces New ADS Repurchase Program

May 7, 2026, 6:45 AM EDT - 3 months ago

BioNTech Announces New ADS Repurchase Program


BioNTech SE Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Earnings Call Transcript: Q1 2026


BioNTech SE Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Earnings release: Q1 2026


BioNTech SE Slides: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Slides: Q1 2026


BioNTech SE Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Earnings Call Transcript: Q4 2025


BioNTech SE Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Annual report: Q4 2025


BioNTech SE Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Earnings release: Q4 2025


BioNTech SE Slides: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Slides: Q4 2025


Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:40 AM EDT - 5 months ago

Scientists behind COVID-19 vaccine will depart BioNTech


BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:50 AM EDT - 5 months ago

BioNTech Cofounders to Leave to Form New Company


BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025, 8:17 AM EST - 10 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE


BioNTech SE Transcript: R&D Day

Nov 11, 2025, 9:00 AM EST - 10 months ago

BioNTech SE Transcript: R&D Day


BioNTech SE Slides: R&D Day

Nov 11, 2025, 9:00 AM EST - 10 months ago

BioNTech SE Slides: R&D Day


BioNTech SE Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Earnings Call Transcript: Q3 2025


BioNTech SE Earnings release: Q3 2025

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Earnings release: Q3 2025


BioNTech SE Slides: Q3 2025

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Slides: Q3 2025


BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:47 AM EST - 10 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment


BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 28, 2025, 7:45 AM EDT - 10 months ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025


taxplanr
taxplanr Aug. 20 at 6:46 PM
$BNTX doesn't their ceo like to talk about unpublished results like $MRNA
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 20 at 6:16 PM
ARCT Defies mRNA Selloff And Extends Rally As Moderna, BioNTech Shares Pull Back $ARCT $MRNA $BNTX https://stocktwits.com/news/equity/markets/arct-defies-m-rna-selloff-and-extends-rally-as-moderna-bio-n-tech-shares-pull-back/cZYIDxYRJZZ
0 · Reply
cubie
cubie Aug. 20 at 5:05 PM
$MRNA peas in a pod $BNTX barely down there and $TEM been nice.green all day
0 · Reply
eightytwentie
eightytwentie Aug. 20 at 3:46 PM
$BNTX man just a bunch of bots pumping and peddling other shyt stocks lately on this board
0 · Reply
NodeInvestmentGroup
NodeInvestmentGroup Aug. 20 at 2:52 PM
$BNTX remains a major biotechnology company focused on innovative medicines and next-generation healthcare technologies. AERT’s operating income jumped 310% year over year to $3.4 million, highlighting substantial improvement in core profitability.
0 · Reply
WavefrontSecurities
WavefrontSecurities Aug. 20 at 2:51 PM
$BNTX remains a major biotechnology company focused on innovative medicines and next-generation healthcare technologies. AERT’s operating income jumped 310% year over year to $3.4 million, highlighting substantial improvement in core profitability.
0 · Reply
SmartSigma
SmartSigma Aug. 20 at 2:28 PM
$BNTX I think the most impressive part of the Q2 release is that they did this without massive dilution they are growing organically from sales not from issuing shares that kind of clean growth is very rare and it makes the valuation look even more absurd
0 · Reply
clubb
clubb Aug. 20 at 2:19 PM
$BNTX bullish but still to early to buy
0 · Reply
tkstockpicker
tkstockpicker Aug. 20 at 1:49 PM
$BNTX added
0 · Reply
DonCorleone77
DonCorleone77 Aug. 20 at 11:54 AM
$MRNA $MRK $BNTX Leerink says cancer vaccine win should sustain Merck momentum into fall Leerink notes Merck (MRK) and Moderna (MRNA) announced the top-line recurrence-free survival and distant metastasis-free survival success of the Phase 3 INTerpath-001 study of INT plus pembrolizumab in completed resected Stage IIB to IV melanoma. With this "unexpected Phase 3 success" of intismeran autogene combined with pembrolizumab in adjuvant melanoma, the firm expects positive investor reaction that will sustain momentum for Merck into the fall. The result is also positive, in Leerink's view, for cancer vaccine-levered stocks, but this no longer BioNTech (BNTX) and the firm expects any BioNTech gains today to fade as investors absorb the poor read-through. The firm has an Outperform rating on Merck.
0 · Reply
GordoHLYK13
GordoHLYK13 Aug. 20 at 10:09 AM
$BNTX $CAPR $IBRX $IGC $SLS$MRNA could be an intriguing strategic beneficiary if $IGC’s IGC-AD1 Phase 2 data validate a new cannabinoid-based approach to Alzheimer’s agitation—potentially opening the door to broader CNS opportunities, partnerships, or acquisition interest around innovative treatments.”
0 · Reply
GordoHLYK13
GordoHLYK13 Aug. 20 at 8:17 AM
$IGC $SLS $IBRX $CAPR $BNTX CALMA Phase 2 Alzheimer's trial is within just six randomizations of closing enrollment, setting up top-line data readout in Q4
0 · Reply
CarrieSpence437
CarrieSpence437 Aug. 20 at 7:39 AM
$BNTX $LPLA $EIX $PBA $NMR BioNTech remains focused on oncology and vaccine development, LPL Financial benefits from advisor and asset growth, Edison International provides regulated utility exposure, Pembina Pipeline benefits from Canadian energy infrastructure, and NMR remains execution-dependent. I'm watching clinical milestones, market levels, power demand, energy volumes, and liquidity.
0 · Reply
SethHarling755
SethHarling755 Aug. 20 at 7:02 AM
$BNTX $UPST $MCD $AMTM BioNTech advances oncology and immunotherapy programs, Upstart remains sensitive to consumer-credit conditions, McDonald's benefits from global restaurant demand, and AMTM remains execution-dependent. I'm watching clinical milestones, credit performance, same-store sales, contracts, and margins.
0 · Reply
TNNStockAnalysisNews
TNNStockAnalysisNews Aug. 20 at 5:47 AM
Top Stock Gainers Today (August 19, 2026): $MRNA — Closed at $174.38, Up an Almost Unbelievable 176.97% $BNTX — Closed Near $111.55-$112.17, Up as Much as 22.9% $MRK — Trading Up to $152.20, Gaining as Much as 12.6% to a Record High $KC — Rising 10.6% on a Surprise Break-Even Quarter $NVAX — Climbing More Than 7% on Sector-Wide Vaccine Momentum https://truthsandnews.com/markets/top-stock-gainers-today-august-19-2026-moderna-explodes
0 · Reply
I_Value_Life
I_Value_Life Aug. 20 at 5:44 AM
$BNTX sold my last lot here, cutting my losses..
0 · Reply
eightytwentie
eightytwentie Aug. 20 at 3:48 AM
$BNTX this is Biontech all year baby
0 · Reply
Bullish_Wicks
Bullish_Wicks Aug. 20 at 3:42 AM
$MRVI $BNTX Best ticker heading into tomorrow PWCM! This Crypto play is setting up for a monster move, insanely small float and fits the theme! Make sure to put PWCM on ur watch bulls!
0 · Reply
Swift_Trades
Swift_Trades Aug. 20 at 3:25 AM
$MRNA Similar upcoming potential catalysts... 😁 BioNTech ($BNTX) BNT113 mRNA immunotherapy for HPV16+ PD-L1+ head/neck cancer; Phase 3 interim PFS data expected later 2026. Geron ($GERN) imetelstat (telomerase inhibitor) for R/R myelofibrosis; Phase 3 OS interim analysis due 2H 2026. Kodiak ($KOD) Zenkuda/KSI-501 for wet AMD; Phase 3 DAYBREAK topline Sept 2026. Rank by likelihood of positive readout: 1. BNTX (Fast Track + prior signals, mRNA parallel to MRNA). 2. GERN (strong Phase 2 OS data). 3. KOD.
1 · Reply
mollielatham
mollielatham Aug. 20 at 12:06 AM
$BNTX has always been higher than MRNA---PLUS more $ and more drugs in phase 3---
0 · Reply
mollielatham
mollielatham Aug. 20 at 12:02 AM
$BNTX cash cash cash in the bank--alot more than MRNA
0 · Reply
Spicy_Trade
Spicy_Trade Aug. 19 at 11:54 PM
BioNTech SE ( $BNTX ) SpicyTrade - Daily Stock Analysis https://youtu.be/3qkRt-9yUJA?si=yiNPf-QNfvOBN4v-
0 · Reply